Shattuck Labs Expands SL-325 Into Phase 2 Hidradenitis Suppurativa Trial, Adds Clinical Development SVP
STTK has more than doubled off its 52-week low of $1.7 on elevated volume (2.9× avg).
Summary
Shattuck Labs is expanding its lead drug SL-325 into a Phase 2 trial for hidradenitis suppurativa, with an IND submission expected this month and 16-week data due in H1 2028. This broadens the drug's opportunity beyond the pivotal Phase 2b trial already planned for Q3 2026. The company also named Shoba Ravichandran, M.D., as SVP of Clinical Development, strengthening its execution team. Cash runway into 2029 remains intact, so the new trial is funded. The appointment and pipeline expansion signal confidence in SL-325's potential across multiple inflammatory indications.
At the time of this announcement, STTK was trading at $6.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $684.5M. The 52-week trading range was $1.70 to $8.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.